GPhA Hopes New OGD Director Supports Fees, Clears Backlog

March 24, 2010
The Generic Pharmaceutical Association (GPhA) expressed hope that the next permanent director of the FDA’s Office of Generic Drugs (OGD) makes clearing the ANDA backlog and establishing generic user fees a top priority. OGD Director Gary Buehler stepped down March 4 and will be temporarily replaced by Keith Webber, deputy director of the Office of Pharmaceutical Science (OPS), which oversees the OGD, OPS Director Helen Winkle said.
Generic Line